Fundraising FoxKern Capital, LLC — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)Sean Harper Desmond Padhi(Founder)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)inDeborah Palestrant(Director)in
PartnerJay Kern· solo GP
Co-investors5AM VenturesAccess BiotechnologyAscenta CapitalForesite CapitalSanofi VenturesWestlake Village BioPartners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.